196 related articles for article (PubMed ID: 36782339)
1. Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure.
Bosch A; Poglitsch M; Kannenkeril D; Kolwelter J; Striepe K; Ott C; Rauh M; Schiffer M; Achenbach S; Schmieder RE
ESC Heart Fail; 2023 Jun; 10(3):1635-1642. PubMed ID: 36782339
[TBL] [Abstract][Full Text] [Related]
2. Novel Cardiac Intracrine Mechanisms Based on Ang-(1-12)/Chymase Axis Require a Revision of Therapeutic Approaches in Human Heart Disease.
Reyes S; Varagic J; Ahmad S; VonCannon J; Kon ND; Wang H; Groban L; Cheng CP; Dell'Italia LJ; Ferrario CM
Curr Hypertens Rep; 2017 Feb; 19(2):16. PubMed ID: 28233239
[TBL] [Abstract][Full Text] [Related]
3. Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind, placebo-controlled exploratory trial.
Antlanger M; Domenig O; Kaltenecker CC; Kovarik JJ; Rathkolb V; Müller MM; Schwaiger E; Hecking M; Poglitsch M; Säemann MD; Kopecky C
Diabetes Obes Metab; 2022 May; 24(5):816-826. PubMed ID: 34984822
[TBL] [Abstract][Full Text] [Related]
4. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.
Verma S; Dhingra NK; Butler J; Anker SD; Ferreira JP; Filippatos G; Januzzi JL; Lam CSP; Sattar N; Peil B; Nordaby M; Brueckmann M; Pocock SJ; Zannad F; Packer M;
Lancet Diabetes Endocrinol; 2022 Jan; 10(1):35-45. PubMed ID: 34861154
[TBL] [Abstract][Full Text] [Related]
5. The role of renin angiotensin system in the pathophysiology of rheumatoid arthritis.
Moreira FRC; de Oliveira TA; Ramos NE; Abreu MAD; Simões E Silva AC
Mol Biol Rep; 2021 Sep; 48(9):6619-6629. PubMed ID: 34417705
[TBL] [Abstract][Full Text] [Related]
6. The renin-angiotensin system and experimental heart failure.
Wollert KC; Drexler H
Cardiovasc Res; 1999 Sep; 43(4):838-49. PubMed ID: 10615411
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
[TBL] [Abstract][Full Text] [Related]
8. Effects of angiotensin-converting-enzyme inhibitor therapy on the regulation of the plasma and cardiac tissue renin-angiotensin system in heart transplant patients.
Kovarik JJ; Kopecky C; Antlanger M; Domenig O; Kaltenecker CC; Werzowa J; Hecking M; Mahr S; Grömmer M; Wallner C; Aumayr K; Kain R; Zuckermann A; Poglitsch M; Säemann MD
J Heart Lung Transplant; 2017 Mar; 36(3):355-365. PubMed ID: 27773450
[TBL] [Abstract][Full Text] [Related]
9. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
Spinale FG; de Gasparo M; Whitebread S; Hebbar L; Clair MJ; Melton DM; Krombach RS; Mukherjee R; Iannini JP; O SJ
Circulation; 1997 Oct; 96(7):2385-96. PubMed ID: 9337215
[TBL] [Abstract][Full Text] [Related]
10. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
Jorde UP; Ennezat PV; Lisker J; Suryadevara V; Infeld J; Cukon S; Hammer A; Sonnenblick EH; Le Jemtel TH
Circulation; 2000 Feb; 101(8):844-6. PubMed ID: 10694521
[TBL] [Abstract][Full Text] [Related]
11. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: II. Effects on myocyte contractile processes.
Spinale FG; Mukherjee R; Iannini JP; Whitebread S; Hebbar L; Clair MJ; Melton DM; Cox MH; Thomas PB; de Gasparo M
Circulation; 1997 Oct; 96(7):2397-406. PubMed ID: 9337216
[TBL] [Abstract][Full Text] [Related]
12. ACE inhibitors and angiotensin receptor blockers differentially alter the response to angiotensin II treatment in vasodilatory shock.
Leisman DE; Handisides DR; Busse LW; Chappell MC; Chawla LS; Filbin MR; Goldberg MB; Ham KR; Khanna AK; Ostermann M; McCurdy MT; Adams CD; Hodges TN; Bellomo R;
Crit Care; 2024 Apr; 28(1):130. PubMed ID: 38637829
[TBL] [Abstract][Full Text] [Related]
13. Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF.
Beusekamp JC; Tromp J; van der Wal HH; Anker SD; Cleland JG; Dickstein K; Filippatos G; van der Harst P; Hillege HL; Lang CC; Metra M; Ng LL; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zwinderman AH; Rossignol P; Zannad F; Voors AA; van der Meer P
Eur J Heart Fail; 2018 May; 20(5):923-930. PubMed ID: 29327797
[TBL] [Abstract][Full Text] [Related]
14. Elevated Angiotensin 1-7/Angiotensin II Ratio Predicts Favorable Outcomes in Patients With Heart Failure.
Wang K; Basu R; Poglitsch M; Bakal JA; Oudit GY
Circ Heart Fail; 2020 Jul; 13(7):e006939. PubMed ID: 32580658
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.
Wolf G; Ritz E
Kidney Int; 2005 Mar; 67(3):799-812. PubMed ID: 15698420
[TBL] [Abstract][Full Text] [Related]
16. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
17. Acute effects of angiotensin-converting enzyme inhibition versus angiotensin II receptor blockade on cardiac sympathetic activity in patients with heart failure.
Azevedo ER; Mak S; Floras JS; Parker JD
Am J Physiol Regul Integr Comp Physiol; 2017 Oct; 313(4):R410-R417. PubMed ID: 28679681
[TBL] [Abstract][Full Text] [Related]
18. The renin-angiotensin system and its vasoactive metabolite angiotensin-(1-7) in the mechanism of the healing of preexisting gastric ulcers. The involvement of Mas receptors, nitric oxide, prostaglandins and proinflammatory cytokines.
Pawlik MW; Kwiecien S; Ptak-Belowska A; Pajdo R; Olszanecki R; Suski M; Madej J; Targosz A; Konturek SJ; Korbut R; Brzozowski T
J Physiol Pharmacol; 2016 Feb; 67(1):75-91. PubMed ID: 27010897
[TBL] [Abstract][Full Text] [Related]
19. Effects of angiotensin receptor blocker at discharge in patients with heart failure with reduced ejection fraction: Korean Acute Heart Failure (KorAHF) registry.
Choi KH; Lee GY; Choi JO; Jeon ES; Lee HY; Cho HJ; Lee SE; Kim MS; Kim JJ; Hwang KK; Chae SC; Baek SH; Kang SM; Choi DJ; Yoo BS; Kim KH; Park HY; Cho MC; Oh BH
Int J Cardiol; 2018 Apr; 257():168-176. PubMed ID: 29506690
[TBL] [Abstract][Full Text] [Related]
20. Physical Exercise and ACE2-Angiotensin-(1-7)-Mas Receptor Axis of the Renin Angiotensin System.
Nunes-Silva A; Rocha GC; Magalhaes DM; Vaz LN; Salviano de Faria MH; Simoes E Silva AC
Protein Pept Lett; 2017 Nov; 24(9):809-816. PubMed ID: 28758593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
